Why the study?
Anemia and iron deficiency are common in heart failure and associated with unfavorable outcomes, creating a need for accurate diagnosis and effective treatment.
Do treatments for anemia and iron deficiency improve clinical outcomes and quality of life in patients with heart failure?
Do treatments for anemia and iron deficiency improve clinical outcomes and quality of life in patients with heart failure?
This review highlights that intravenous iron, unlike oral iron or ESAs, effectively improves symptoms and quality of life in heart failure patients with iron deficiency, aligning with current ESC guidelines.
May support iron repletion in anemic HF; leaves open optimal strategies pending larger RCTs.
Introduction Anemia and iron deficiency are common comorbidities in population with heart failure. Their association with unfavorable prognostic outcomes and diminished quality of life underscores the imperative need for accurate diagnosis and efficacious treatment interventions. In recent years numerous treatment options have been explored in clinical trials, aimed at addressing the multifaced aspects of these concurrent conditions. Summary In patients with heart failure effective treatment of anemia and iron deficiency has demonstrated enhancements in quality of life and exercise capacity. Findings from IRONMAN clinical study have prompted revisions in the latest guidelines from the European Society of Cardiology. The imminent release of results from two ongoing trials holds the potential to reshape the therapeutic landscape for treating individuals with heart failure and iron deficiency. Nevertheless, there is no explicit evidence that studied interventions could improve morbidity or risk of hospitalizations.
No takes yet. Share an insight, caveat, or question.
Burek et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: